Essentials

• Type 2N von Willebrand disease involves impaired von
Willebrand factor to factor VIII binding.
• Type 2N von Willebrand disease mutations exhibit qualitative and mild quantitative deficiencies.
• Type 2N von Willebrand disease mice exhibit unstable venous hemostatic thrombi.
• The factor VIII-binding ability of von Willebrand factor regulates arteriole thrombosis dynamics.
Summary. Background: von Willebrand factor (VWF) and factor VIII (FVIII) circulate as a non-covalent complex, with VWF serving as the carrier for FVIII. VWF indirectly influences secondary hemostasis by stabilizing FVIII and transporting it to the site of primary hemostasis. Type 2N von Willebrand disease involves impaired binding of VWF to FVIII, resulting in decreased plasma levels of FVIII. Objectives: In these studies, we characterize the impact of three type 2N VWD variants (R763A, R854Q, R816W) on VWF secretion, FVIII stabilization and thrombus formation in a murine model. Methods: Type 2N VWD mice were generated by hydrodynamic injections of mutant murine VWF cDNAs and the influence of these variants on VWF secretion and FVIII binding was evaluated. In vivo hemostasis and the dynamics of thrombus formation and embolization were assessed using a murine tail vein transection hemostasis model and an intravital thrombosis model in the cremaster arterioles. Results: Type 2N VWD variants were associated with decreased VWF secretion using cell and animalbased models. 
Introduction
Low levels of the coagulation factors von Willebrand factor (VWF) and factor VIII (FVIII) increase the risk of bleeding. von Willebrand disease (VWD) involves quantitative (type 1 and type 3) or qualitative (type 2A, 2B and 2M) defects and results in the dysfunction of primary hemostasis with impaired platelet adhesion and aggregation at the site of vessel injury. In contrast, type 2N VWD (involving impaired binding of VWF to FVIII), and hemophilia A, (characterized by quantitative FVIII deficiency), result in impaired secondary hemostasis related to decreased thrombin generation and fibrin formation. The life cycle of FVIII is regulated by its interaction with VWF [1] . Under normal plasma conditions, VWF and FVIII circulate in a tight, non-covalent complex, at a 50 : 1 molar ratio [2, 3] . The VWF-FVIII complex exists in a dynamic equilibrium where 95-98% of circulating FVIII is bound to VWF, with high rates of association and dissociation [2, 4, 5] . Binding of FVIII to VWF modulates its activation by thrombin and protects it from proteolytic degradation by serine proteases [6] and from accelerated clearance [7] [8] [9] [10] . Additionally, it might be hypothesized that VWF spatially regulates FVIII activity by mediating FVIII transport to the site of platelet thrombus formation.
Quantitative deficiencies of VWF are associated with concomitant reduction in FVIII, whereas qualitative abnormalities in the FVIII binding activity of VWF also influence plasma FVIII levels [11, 12] . Type 2N VWD is characterized by VWF:Ag levels in the normal to low range, with plasma FVIII levels between 5% and 30% as a consequence of missense VWF variants resulting in impaired binding of VWF to FVIII [13] . Type 2N VWD patients have a bleeding phenotype that presents in a manner similar to mild to moderate hemophilia A in association with trauma, the postpartum period, occasional hemarthrosis and muscle hematomas [14] . Type 2N VWD is an autosomal recessive condition with missense variants that are predominantly localized to the D'D3 (FVIII-binding) region of VWF. These variants result in the formation of a larger pool of FVIII that is not bound to VWF, thereby increasing the rate of FVIII proteolysis and clearance [15] .
Although the genetic basis for type 2N VWD is relatively well described, the pathophysiologic mechanisms underlying the bleeding phenotype in this patient population remain incompletely characterized [16] . Here, we investigate three 2N VWD variants localized to the D' region or propeptide cleavage site of VWF (Table 1 ) in a murine model. R854Q is the most common 2N allele and is associated with a mild phenotype [17] , whereas R816W is associated with a severe phenotype [18] . Impaired propeptide cleavage involves a substitution at the cleavage site between the propeptide (R763) and mature VWF molecule, which inhibits cleavage by furin, resulting in the release and circulation of the pro-VWF molecule in which the retained propeptide probably sterically hinders FVIII binding to VWF [19, 20] . We utilized alanine scanning mutagenesis to generate the propeptide cleavage variant R763A. The influence of these type 2N VWD variants on quantitative and qualitative aspects of VWF function and the influence of impaired FVIII binding on in vivo thrombus formation and stability are characterized.
Methods
Heterologous VWF expression system and immunofluorescence
Type 2N VWD mutations were introduced into murine VWF cDNA in pCIneo and pSC11 using the Quick-Change II XL Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA); the sites of mutation were conserved across species ( Figure S1 ). The VWF cDNA vectors were transiently transfected using lipofectamine (Life Technologies, Carlsbad, CA, USA) into HEK 293T cells for VWF synthesis and secretion and HEK 293 cells for immunofluorescence. Pseudo-Weibel Palade body (WPB) formation was imaged using a rabbit anti-VWF antibody (Dako, Glostrup, Denmark). Confocal microscopy was performed using a Quorum Wave FX-X1 spinning disc confocal system.
FVIII and collagen binding assay
FVIII binding was assessed using a modified solid phase binding assay where murine plasma-derived VWF produced by hydrodynamic injections of the murine VWF cDNA into VWF-FVIII double knockout (DKO) mice was immobilized with a polyclonal rabbit anti-human VWF antibody. Binding to recombinant full-length human FVIII (Bayer, Leverkusen, Germany) was detected with a sheep anti-FVIII HRP antibody (Affinity Biologicals, Ancaster, ON, Canada). Collagen binding was characterized as previously described using bovine type I collagen (MP Biomedicals, Santa Ana, CA, USA) [21, 22] .
Western blot and multimers
For western blot of the VWF monomer, murine plasmaderived VWF was denatured in and run on a mini-gel under reducing conditions. VWF multimeric profiles were confirmed by 1% SDS agarose gel electrophoresis. Blots were probed with an HRP-conjugated rabbit anti-human VWF antibody (Dako) [23, 24] .
Transgenic type 2N VWD mice and plasma-derived VWF In vivo expression was induced via hydrodynamic tail vein injections of the murine VWF cDNA containing the type 2N VWD variants under the enhanced murine transthyretin (ET) promoter in VWF knockout (KO) C57BL/6 mice [23] , which induces variable VWF expression. For all studies, VWF:Ag levels were measured by ELISA using rabbit antihuman VWF antibodies A0082 and P0226 (Dako) and 
Intravital microscopy and analysis
Thrombus formation in the murine cremaster arterioles was performed as previously described [25] . Platelets were labeled in vivo using DiOC 6 (20 nM/mouse) (Invitrogen, Grand Island, NY, USA), and immediately prior to vessel injury, mice were injected with the photosensitizing agent hematoporphyrin (50 lg/dose) (Sigma Aldrich, St Louis, MO, USA). Injury was induced by simultaneous irradiation and excitation with a 491-nm laser for up to 10 min. As the site of vessel injury was limited to only the field of laser irradiation, mice were injured three to five times each in different arterioles. Images were captured with a Quorum WaveFX-X1 spinning disk confocal microscope (Quorum Technologies Inc., Guelph, Canada) and Hamamatsu Orca high-resolution camera (Hamamatsu, Japan). Quantitative analysis of intravital images using ImageJ software (1.47v, National Institute of Health, Bethesda, MA, USA) was performed from t = 0 (thrombus initiation) for 10 min or until ischemic blood flow was observed. Time to occlusion was defined as the point at which the thrombus contacted both vessel walls. For particle analysis, images were subjected to threshold assignment to create binary images and the vessel area was gated to define the area of analysis. Particle analysis was performed on objects > 4.5 lm 2 in size to eliminate noise and analysis of single platelets. Thrombus volume was calculated as the average per cent of the vessel over the course of the injury. The average number of thrombi and the average size of thrombi were calculated over the course of the injury. Thrombus stability was measured as a loss of threshold material between two subsequent frames and classified as small (45- 
Tail vein transection (TVT)
Assessment of bleeding in response to TVT was performed as recently described in detail [26] . For experimental conditions, 300 U kg À1 wild type or R816W VWF was administered i.v. to VWF KO mice 2 h prior to TVT in order to allow for endogenous FVIII stabilization ( Table 2 ). As primary hemostasis may be impaired in VWF-deficient mice despite the infusion of murine VWF, animals were not excluded based on their primary bleeding times. Blood loss was quantified by hemoglobin concentrations using a human purified hemoglobin standard.
Statistics
Statistical analysis using t-tests or one-way analysis of variance with Tukey or Dunnett post hoc analysis was performed on experiments with an n ≥ 3 using GraphPad InStat3 software (San Diego, CA, USA). Fisher's exact tests were performed with GraphPad Prism6. Values are expressed as means AE standard error. Figures denote P < 0.05 with * and P < 0.001 with **.
Results
Type 2N VWD variants are associated with impaired VWF secretion
The influence of type 2N VWD variants on VWF synthesis or secretion was measured in vitro by transient . HEK 293T cells were transiently transfected with type 2N VWD variant murine cDNAs and immunofluorescence was performed (C). Murine plasma-derived type 2N VWD proteins generated in VWF/FVIII double knockout (DKO) mice were assessed for FVIII binding activity (D) and collagen binding activity (F). Influences of type 2N VWD variants on VWF multimerization (G) and propeptide retention (E) were assessed. N = 3-6 independent experiments; AE SE, *P < 0.05, **P < 0.001. [Color figure can be viewed at wileyonlinelibrary.com] Co-transfection of the R854Q VWF cDNA with the wild type VWF cDNA resulted in a partial rescue of VWF:Ag secretion. Punctate pseudo-WPB were observed in HEK 293 cells expressing wild type, R763A and R816W variants, whereas VWF staining was more diffuse in cells expressing the R854Q variant (Fig. 1C) .
In vivo VWF expression was induced by hydrodynamic tail vein delivery of the murine VWF cDNA (singly to represent the homozygous condition or in combination to represent a heterozygous condition). Mice were monitored via retro-orbital sampling over a 21-day period; VWF levels were highly variable and supraphysiological. To minimize the influence of extremely high levels of VWF (> 10 U mL À1 ) data from week 1 were omitted from this analysis. For type 2N VWD variants, a trend of lower VWF:Ag for the R854Q and R763A variants was observed relative to wild type VWF ( Fig. 2A) . As decreased plasma levels of VWF may also be related to accelerated clearance, we measured the half-life of plasma-derived type 2N VWD variants (Fig. 3A ,B) in VWF-deficient mice. The half-life of type 2N VWD variants was not significantly different relative to that of wild type variants (Fig. 3C) .
The structure and qualitative function of type 2N VWD variants were also assessed. Collagen binding and multimeric analysis of plasma-derived type 2N VWD variants was not significantly different from that of wild type variants (Fig. 1F,G) [21, 22] . The R763A variant retains the 741 amino acid propeptide in approximately 50% of the mature VWF molecules (Fig. 1E) , as demonstrated by western blotting under reducing conditions.
Type 2N VWD variants were associated with impaired FVIII binding and stabilization in vitro and in vivo
The influence of type 2N VWD variants on FVIII binding and stabilization was measured in vitro using a solid phase binding assay and in vivo in type 2N VWD transgenic mice. Relative to wild type, type 2N VWD variants all displayed decreased FVIII binding (Fig. 1D) . In VWF KO mice, plasma levels of FVIII:C are significantly reduced (9-20%) relative to wild type [27, 28] . Hepatic expression of wild type VWF stabilized endogenous plasma FVIII (Fig. 2B) . For the type 2N VWD variants, variable partial stabilization of endogenous FVIII:C was observed relative to normal levels, with the R816W variant demonstrating a total absence of FVIII stabilization.
In vivo FVIII stabilization was also measured in VWF KO mice infused with plasma-derived murine VWF (FVIII-free). Although the recovery of VWF:Ag after 5 min ( Figure S3A ) and half-life of 2N VWD variants (Fig. 3A-C) were not significantly different, the ability of these variants to stabilize endogenous FVIII:C in this model was highly impaired (Fig. 3D,E) , as confirmed by Area under curve (AUC) analysis (Fig. 3F) and FVIII: VWF ratios ( Figure S2 (Fig. 3D) .
Impaired VWF-FVIII binding was associated with increased bleeding and decreased hemostatic thrombus stability in a murine tail vein transection (TVT) model
The influence of VWF-FVIII binding on hemostatic thrombus formation was assessed in a murine TVT model. VWF KO mice received tail vein injections of wild type or severe type 2N VWF (R816W) (300 U kg À1 ) 2 h prior to transection of the left lateral tail vein in order to allow for stabilization of endogenous FVIII. Relative to wild type mice, FVIII deficiency was associated with increased bleeding time (Fig. 4A ) and blood loss (Fig. 4B) . Similarly, although infusion of plasma-derived wild type VWF into VWF KO mice produced stable hemostasis, mice infused with severe 2N VWF (R816W) showed an increased bleeding time and increased blood loss. Interestingly, both FVIII KO mice and type 2N mice had a higher rate of spontaneous re-bleeding events (depicted in Figure S4 ) as compared to control animals (Fig. 4C) .
Impaired VWF-FVIII binding was associated with decreased thrombus formation and stability in a murine intravital arteriole model
We characterized our type 2N VWD murine model using spinning disc confocal intravital microscopy of laser-induced thrombosis in the cremaster arteriole. As previously reported, the hematoporphyrin-mediated photochemical injury induced platelet thrombus formation in a VWF-dependent manner, as vessel occlusion was rare in VWF KO or VWF/FVIII double KO mice (Fig. 5A) [25] . We also evaluated the influence of FVIII on thrombus formation and stability in this model using FVIIIdeficient mice, where occlusion time relative to wild type animals was slightly but not significantly increased (Fig. 5A) . However, in FVIII-deficient mice, a significant decrease in the total amount of thrombus generated (Fig. 5B ) and in the number of thrombi formed (Fig. 5D ) was observed relative to wild type mice. This was also related to a significant increase in large embolic events observed in the absence of FVIII (Fig. 5F ).
The influence of the severe 2N VWD variant (R816W) on thrombus formation and stability was evaluated relative to wild type VWF. In mice expressing the severe type 2N VWD variant R816W, plasma VWF:Ag was not significantly different from wild type controls immediately prior to intravital analysis ( Figure S3B ) although plasma FVIII:C remained 15-20% of normal (Fig. 2B ). Time to vessel occlusion was slightly increased for R816W VWF, whereas thrombus volume, average thrombus size and number of thrombi were significantly decreased compared with wild type (Fig. 5A-D) . R816W VWF was associated with a greater frequency of small embolic events (Fig. 5E ) compared with wild type. Finally, to assess VWF transport of FVIII to the thrombus, plasma FVIII stabilization was controlled by i.v. injection of VWF into VWF KO mice (FVIII:C~15%) immediately prior to the initiation of vessel injury. For mice infused with R816W VWF, time to occlusion was slightly delayed relative to mice infused with wild type VWF (Fig. 6A ). Thrombus volume (Fig. 6B) and number of thrombi (Fig. 6C) were decreased for R816W VWF-infused mice relative to wild type; however, average thrombus size and frequency of embolization were not significantly different ( Figure S7 ).
Discussion
Recent studies have provided a detailed characterization of the molecular basis of the interaction between VWF and FVIII. Binding primarily occurs between the FVIII C1 and VWF D' domains but includes additional points of contact between the VWF D3 domain and the FVIII A3, a3 and C2 regions [29, 30] . The D' region of VWF contains a flexible TIL' loop containing multiple arginine residues that creates a high positive charge density that may allow for docking of acidic FVIII regions [31] . The majority of severe type 2N VWD variants are localized to this region and involve either a loss of a cysteine residue involved in disulfide bond formation or a loss of positive charge.
This study reports for the first time the influence of type 2N VWD D' arginine variants (R816W, R854Q) and a propeptide cleavage variant (R763A) on VWF-FVIII interactions in a murine model. We first assessed the influence of our murine type 2N VWD variations on VWF synthesis and secretion. Collectively within published case studies, the VWF variant database and the Canadian VWD patient population, individuals homozygous for the R854Q variant have reported VWF:Ag between 41% and 122%, and between 15% and 125% for the R763G variant [11, 19, [32] [33] [34] [35] [36] [37] [38] . Interestingly, the R854Q variant has been identified in approximately 1% of type 1 VWD families in three separate multicenter studies [11, 36, 37] . We observed that the 2N VWD variants R854Q and R763A are associated with impaired secretion in both in vitro and in vivo systems, although the magnitude of the quantitative deficiency was variable (Figs. 1A and 2A) . The R854Q variant displayed a significant decrease in secretion from transiently HEK 293 cells (~5%) and in vivo (~40%). The R763A variant secreted at 70% in vitro and~40% in vivo. These observations are consistent with previous reports showing impaired secretion of human R854W in HEK 293 cells (~12%) [34] and R763G (~67%) [19] VWF.
However, the severe murine R854Q VWF secretion defect in HEK 293 cells is in contrast to human R854Q VWF, which is secreted at~100% of wild type in COS-7 cells,~50% of wild type in AtT-20 cells and~40% of normal from blood outgrowth endothelial cells (BOECs) [35, 39, 40] . WPB or pseudo-WPB formation of human R854Q VWF in patient-derived BOECs, AltT-20 and HEK 293 cells appears normal [40] [41] [42] [43] . However, the human R854W VWF demonstrated a diffuse VWF staining pattern in HEK 293 cells, which was similar to our murine R854Q variant [34] . Collectively, these studies suggest that variation at the VWF R854 position can influence VWF secretion. The extent of this defect is likely to be dependent on the physiochemical differences between the variant amino acids, and the genetic context in which this variant occurs, including amino acid sequence differences between human and murine VWF cDNAs or the genotype of additional VWF-modifying loci such as ABO. Finally, the cellular system used for heterologous expression studies (where AtT-20 and HEK 293 cells form pseudo-WPB and Cos-7 cells and murine hepatocytes do not) and overexpression of VWF under the CMV promoter may also influence subcellular VWF localization.
Overall, however, in type 2N VWD patients, VWF:Ag levels may be highly variable, and instances of low VWF levels are frequently observed. The association between low VWF levels in type 2N VWD is not limited to the variants characterized in our study, as additional type 2N VWD variants (e.g. C788R, C858F, D879N and C1225G) are associated with low VWF plasma levels and/or VWF secretion defects [44] [45] [46] [47] . Taken together, these data suggest that some classical type 2N variants may impair VWF secretion, which, in combination with a qualitative FVIII-binding defect, contributes to a more severe quantitative FVIII deficiency and exacerbates the bleeding phenotype in type 2N VWD. We next assessed the influence of type 2N VWD variants on FVIII stabilization in two murine models. In the first model, transgenic expression of the murine VWF cDNA was induced via hydrodynamic tail vein injections into VWF KO mice, and plasma VWF:Ag and FVIII:C were monitored over a 3-week period (Fig. 2) . In response to VWF expression, plasma FVIII:C was variably increased in our type 2N VWD mice except for the R816W variant that showed no appreciable FVIII stabilization. In the second model, we infused plasmaderived VWF (FVIII-free) into VWF KO mice and measured FVIII stabilization (Fig. 3) . In these studies, plasma FVIII:C levels were partially stabilized by mild/moderate type 2N VWD variants (R763A, R854Q) compared with wild type variants following infusion of the VWF proteins, whereas the R816W VWF variant failed to stabilize endogenous FVIII. Area under curve analysis confirmed significant differences in endogenous FVIII stabilization over a 24-h period. The discrepancy in FVIII stabilization between the two experimental models is likely to be related at least in part to the level of VWF expression in the hydrodynamic model. When VWF levels are supraphysiological, the available number of FVIII binding sites is significantly increased. Although mild/moderate type 2N VWD variants have a lower affinity binding site for FVIII, the increased avidity may still favor the association of FVIII with VWF rather than increasing the pool of FVIII circulating VWF-free. However, when VWF was dosed and administered at equimolar physiological levels, the FVIIIbinding defect of the mild/moderate type 2N VWD variants became evident. These results agree with the clinical observation that some milder type 2N cases still benefit from the administration of desmopressin through the release of more VWF molecules, albeit with lower affinity FVIII binding sites [38] .
Interestingly, partial propeptide cleavage was observed with the R763A murine variant (Fig. 1E ) compared with the total lack of cleavage seen with the R763G variant in humans [19, 20] . Partial furin processing at this cleavage site is consistent with the relatively conservative amino acid substitution we have introduced in our R763A variant, and with the milder 2N phenotype demonstrated by this variant.
VWF regulates FVIII hemostatic activity by stabilizing plasma FVIII levels, and may also facilitate transport of FVIII to the site of platelet thrombus formation, thereby increasing localized FVIII concentrations at the endothelial cell and platelet surface, the major sites of intrinsic tenase activity [48, 49] . We observed that in the murine TVT model, thrombus formation was impaired in mice infused with the severe type 2N VWD variant protein (R816W) as compared with wild type controls (Fig. 4) . We documented decreased thrombus stability, as measured by spontaneous re-bleeding, in both FVIII KO mice and mice that received the severe type 2N VWD variant protein.
To evaluate the influence of type 2N VWD on the dynamics of thrombus formation, we performed intravital microscopy using a murine cremaster arteriole thrombosis model. Methods for observing the intravital hemostatic activity of FVIII and VWF can vary widely [50] [51] [52] and vessel occlusion and robust thrombus formation is not always observed in the absence of FVIII [52, 53] . This may be related to the generation of an injury involving endothelial disruption and thrombus formation driven . von Willebrand factor (VWF)-FVIII interactions influence hemostatic thrombus formation and stability in a murine bleeding mode. Hemostatic thrombus formation was evaluated in a murine tail vein transection model using either wild type (WT) or severe type 2N (R816W) VWF. Hemostasis was measured by quantifying (A) total bleeding time and (B) total hemoglobin loss. The proportion of animals in each condition that experienced a spontaneous re-bleed during the course of the assay was assessed (C). N = 6-9 animals per condition; AE SE, *P < 0.05, **P < 0.001.
predominantly by secondary hemostasis. By contrast, the photochemical injury we employed in these studies results in platelet plug formation mediated by VWF in the absence of endothelial cell denudation [25] . Importantly, occlusive thrombi were routinely formed in FVIII KO or type 2N VWD mice (Fig. 5) ; however, quantitative particle analysis demonstrated decreased total thrombus formation and increased rate of embolization, highlighting the essential role of FVIII in regulating thrombus formation and stability. Similarly, when we evaluated the The influence of these genotypes on time to vessel occlusion (A) was assessed. Total thrombus volume (B), average thrombus size (C) and average number of thrombi generated (D) were calculated by particle analysis with ImageJ software. The influence of VWF-FVIII binding on thrombus stability was characterized as either small (E) or large (D) embolic events. N = 4-6 animals per condition; AE SE, *P < 0.05, **P < 0.001, average (AVG)
influence of wild type and severe 2N VWF immediately after infusion and prior to stabilization of endogenous FVIII, an overall decrease in thrombus formation was observed (Fig. 6 ). Taken together, our TVT and intravital experiments indicate that the bleeding phenotype in 2N VWD patients is the consequence of impaired thrombus stabilization. Further, these studies suggest that VWF binding to FVIII can regulate thrombus formation and stability by bringing FVIII to the site of platelet activation and endothelial injury [48, 49] . Although the essential role of VWF platelet-and collagen-binding abilities in regulating both physiological hemostasis and arterial thrombosis has been previously described [54] [55] [56] , this is the first study to demonstrate the importance of the FVIII-binding capacity of VWF in regulating thrombus dynamics in both physiological and pathobiological contexts. Consistently, VWF and FVIII regulate venous thrombus stability [57] and supraphysiological FVIII levels can increase arterial thrombus stability [58] .
There are several limitations to the mouse models employed in these studies. Hepatic expression of VWF reconstitutes the plasma VWF compartment ('plasma phase') only. As very recent evidence suggests that the majority of VWF and FVIII is not produced in the same endothelial beds [59] , VWF and FVIII probably first associate in the plasma; therefore, the lack of endothelial or platelet-derived VWF is not likely to significantly impact the characterization of the type 2N VWD phenotype in our model. The variable supraphysiological expression of VWF induced by the hydrodynamic procedure, however, may alter evaluation of the true FVIII-binding capacity of type 2N variant VWF. The multimer content of VWF produced following hydrodynamic transgene delivery often lacks the largest VWF multimers, and therefore slightly higher VWF:Ag (~2 U mL À1 ) levels were used to evaluate hemostatic efficacy of these proteins in this study.
The VWF expression studies reported here have extended previous reports of the inclusion of the R854Q 2N variant in type 1 VWD populations, suggesting that some classic type 2N variants can display both qualitative and mild quantitative VWF deficiencies that together contribute to low plasma FVIII levels. Moreover, these studies are the first to characterize the influence of impaired VWF-FVIII binding on arteriole and venous thrombus formation dynamics in vivo, and demonstrate that bleeding in hemophilia and type 2N VWD is related in part to defective stabilization of the platelet plug. Collectively, these data support the observation that strategies that improve hemostatic thrombus stability such as antifibrinolytic therapy are complementary to clotting factor replacement in resolving bleeding in cases of mild quantitative FVIII deficiencies. Further, the development of novel hemophilia therapies that are lacking the co-localizing and complementary functional roles of VWF and FVIII may result in hemostatic responses that are both quantitatively and qualitatively non-physiological. 
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